IP Library › Granted Patent US 10,703,821
Granted Patent B2
US 10,703,821 · App. 14/480,586 · Granted Jul 7, 2020

Method for stimulating or enhancing proliferation of cells by activating the mucin 1 (MUC1) receptor

Inventor: Cynthia Bamdad (Waltham, MA)
Assignee: Minerva Biotechnologies Corporation
C07K16/3092A61K38/1709A61K38/193A61K38/45A61K38/488A61K38/4886C07K16/2863C07K16/468A61K48/00C07K2317/31C07K2317/35C07K2317/75
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,703,821
App. No.
14/480,586
Granted
Jul 7, 2020
Kind
B2
Abstract

The present application discloses a method for stimulating or enhancing proliferation of a population of cells by activating MUC1 receptor on the cells.

Claims (15)

1. A method for stimulating or enhancing proliferation of a population of cells by activating Mucin 1 (MUC1) receptor on the cells, wherein the activating is carried out by contacting the cells with (i) an agent that dimerizes the MUC1 Growth Factor Receptor (MGFR) portion of MUC1 receptor; (ii) an agent that increases the cleavage of MUC1 receptor to the growth factor receptor form; or (iii) a ligand that activates the MGFR portion of the MUC1 receptor, wherein the cells are non-tumorous cells or immature cells.

2. The method according to claim 1 , wherein the cells are non-tumorous cells.

3. The method according to claim 1 , wherein the cells are immature cells.

4. The method according to claim 3 , wherein the cells are chosen from the group consisting of stem cells, progenitor cells, endometrial cells, neutrophil precursors and neutrophils.

5. The method according to claim 1 , wherein the MUC1 receptor is a cell surface-attached cleavage product.

6. The method according to claim 5 , wherein the MUC1 cleavage product is MGFR.

7. The method according to claim 6 , wherein the MGFR consists essentially of the PSMGFR having the sequence of SEQ ID NO:10.

8. The method according to claim 1 , wherein MUC1 receptor is activated by a dimerizing agent of the MUC1 receptor.

9. The method according to claim 8 , wherein the dimerizing agent is bivalent.

10. The method according to claim 9 , wherein the bivalent agent recognizes a portion of the MGFR.

11. The method according to claim 8 wherein the bivalent agent is a synthetic compound.

12. The method according to claim 8 wherein the bivalent agent is a dimeric ligand of MUC1.

13. The method according to claim 9 , wherein the bivalent agent is an antibody.

14. The method according to claim 1 , wherein agent that increases the cleavage is an enzyme.

15. The method according to claim 14 , wherein the enzyme is TACE/ADAM17 or MMP14.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 7, 2018
From: BAMDAD, CYNTHIA
To: MINERVA BIOTECHNOLOGIES CORPORATION
Reel/Frame 047711/0994 →
Continuity (3)
Division 11278122 · Mar 30, 2006
Provisional Application 60667216 · Mar 30, 2005
Related Publication 20150218288A1 · Aug 6, 2015
Cited By (3)
US 12,195,728 US 12,415,868 US 12,491,259